| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10918217 | Radiotherapy and Oncology | 2015 | 7 Pages |
Abstract
In the majority of patients with CRPC and a symptomatic pelvic tumor, PPRT with 30-39Â Gy contributes to relief of hematuria, pain and other pelvic symptoms, with acceptable toxicity. Future studies should investigate whether PPRT regimens can be simplified.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Marte Grønlie Cameron, Christian Kersten, Ingvild Vistad, Rene van Helvoirt, Kjetil Weyde, Christine Undseth, Ingvil Mjaaland, Eva Skovlund, Sophie D. Fosså, Marianne Grønlie Guren,